SCHEMBL5250281

SCHEMBL5250281

CC(=O)Nc1[c]c(NC(C)=O)cc(NC(C)=O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.56
ALDH1A1 P00352 6/20 0.47
GAA P10253 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
HSD17B10 Q99714 2/20 0.46
HTT P42858 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NAPRT Q6XQN6 1/20 0.46
KMT2A Q03164 6/20 0.46
MEN1 O00255 5/20 0.46
MAPT P10636 4/20 0.45
CA12 O43570 1/20 0.45
BRD4 O60885 1/20 0.45
NR1I2 O75469 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
MB P02144 1/20 0.45
CYP1A1 P04798 1/20 0.45
CA3 P07451 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3071609 0.80 LMNA (0.71) LMNAALDH1A1GAATDP1SMN1; SMN2
SCHEMBL7529744 0.77 LMNA (0.56) LMNAALDH1A1GAATDP1SMN1; SMN2
SCHEMBL1816471 0.76 LMNA (0.54) LMNAALDH1A1GAATDP1SMN1; SMN2
SCHEMBL19304826 0.76 LMNA (0.54) LMNAALDH1A1GAATDP1SMN1; SMN2
SCHEMBL7841883 0.75 ALDH1A1 (0.47) LMNAALDH1A1TDP1SMN1; SMN2HSD17B10
SCHEMBL2161029 0.74 HSD17B10 (0.48) LMNAALDH1A1GAATDP1SMN1; SMN2
SCHEMBL8765733 0.73 LMNA (0.56) LMNAALDH1A1GAATDP1SMN1; SMN2
SCHEMBL1451696 0.72 KMT2A (0.55) LMNAALDH1A1GAASMN1; SMN2HTT
SCHEMBL9770987 0.72 LMNA (0.50) LMNAALDH1A1GAATDP1SMN1; SMN2
SCHEMBL9807676 0.71 LMNA (1.00) LMNAALDH1A1GAATDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1221440-B1 Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators OTSUKA PHARMA CO LTD (JP) 2007-04-25 EP disclosed
US-6642223-B2 A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2003-11-04 US disclosed
EP-0765314-B1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMA CO LTD (JP) 2003-05-07 EP disclosed
EP-1221440-A1 Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators Otsuka Pharmaceutical Company, Limited (JP) 2002-07-10 EP disclosed
US-20020049194-A1 Benzoheterocyclic derivatives OGAWA HIDENORI (JP) 2002-04-25 US disclosed
US-6335327-B1 Benzoheterocyclic derivatives OTSUKA PHARMACEUTICALS CO., LTD. (JP) 2002-01-01 US disclosed
US-6096735-A Benzoheterocyclic derivatives OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 2000-08-01 US disclosed
EP-0778267-A1 SULFONAMIDE DERIVATIVES AND INSECTICIDE, MITICIDE AND NEMATICIDE CONTAINING THE SAME OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1997-06-11 EP disclosed
EP-0765314-A1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-04-02 EP disclosed
WO-1995034540-A1 BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1995-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049194-A1 Benzoheterocyclic derivatives AVPR2, AVPR1A, AVPR1B LMNA 2507/4885ALDH1A1 3145/4885GAA 4193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.